NVAX
Novavax, Inc.$9.10-0.24 (-2.62%)Prev Close$9.35·MCap$1.56B·P/E3.81·Vol3.13M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
3
$488.6K
◆
Net Activity
Net Seller
$488.6K
●
Active Insiders
3
last 12 mo
Over the past 12 months, insider activity at Novavax, Inc. (NVAX) has been exclusively selling, with 0 insider purchases totaling $0.00 and 3 insider sales totaling $488.6K. The most recent insider transaction was by Jacobs John C (President and CEO), who sold $358.8K worth of shares on Jan 23, 2026. Novavax, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.56B.
NVAX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 23, 2026 | Jacobs John C | President and CEO | Sell | 39,132 | $9.17 | $358.8K | 0 |
| Dec 11, 2025 | Casey Mark J | EVP, Chief Legal Officer | Sell | 12,713 | $6.69 | $85.0K | 0 |
| Nov 11, 2025 | Draghia-Akli Ruxandra | Section 16 | Sell | 6,048 | $7.40 | $44.8K | 0 |
| Mar 7, 2025 | Kelly James Patrick | EVP, CFO and Treasurer | Sell | 5,904 | $8.34 | $49.2K | 0 |
| Mar 7, 2025 | Trizzino John | President and COO | Sell | 13,954 | $8.34 | $116.4K | 0 |
| Mar 1, 2025 | Casey Mark J | EVP, Chief Legal Officer | Sell | 1,214 | $8.33 | $10.1K | 0 |
| Mar 1, 2025 | Jacobs John C | President and CEO | Sell | 38,451 | $8.33 | $320.3K | 0 |
| Mar 1, 2025 | Kelly James Patrick | EVP, CFO and Treasurer | Sell | 28,337 | $8.33 | $236.0K | 0 |
| Mar 1, 2025 | O'Hara Elaine | EVP, Chief Strategy Officer | Sell | 16,344 | $8.33 | $136.1K | 0 |
| Mar 1, 2025 | Trizzino John | President and COO | Sell | 23,185 | $8.33 | $193.1K | 0 |
| Jan 2, 2025 | King Rachel K. | Sell | 4,150 | $9.02 | $37.4K | 14,770 | |
| Jan 2, 2025 | YOUNG JAMES F | Sell | 10,000 | $8.22 | $82.2K | 57,160 | |
| Jun 25, 2024 | YOUNG JAMES F | Sell | 7,500 | $14.09 | $105.7K | 61,760 | |
| Jun 21, 2024 | YOUNG JAMES F | Sell | 7,500 | $13.72 | $102.9K | 70,367 | |
| Jun 20, 2024 | Dubovsky Filip | President, R&D | Sell | 13,904 | $14.47 | $201.2K | 68,017 |
| May 15, 2024 | Dubovsky Filip | President, R&D | Sell | 47,312 | $13.90 | $657.6K | 38,953-55% |
| Mar 14, 2023 | Glenn Gregory M | President, R&D | Buy | 6,000 | $7.17 | $43.0K | 14,473+71% |
| Apr 4, 2022 | YOUNG JAMES F | Director | Sell | 12,500 | $73.58 | $919.8K | 66,145 |
| Jan 5, 2022 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 5,000 | $140.91 | $704.5K | 8,445-37% |
| Jan 4, 2022 | YOUNG JAMES F | Director | Sell | 3,750 | $144.16 | $540.6K | 75,090 |
| Dec 22, 2021 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 5,000 | $230.00 | $1.15M | 3,845-57% |
| Dec 16, 2021 | Glenn Gregory M | President, R&D | Sell | 1,686 | $174.13 | $293.6K | 7,232 |
| Dec 9, 2021 | Glenn Gregory M | President, R&D | Sell | 8,250 | $170.14 | $1.40M | 12,111-41% |
| Dec 3, 2021 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 5,000 | $196.19 | $980.9K | 7,069-41% |
| Dec 2, 2021 | Glenn Gregory M | President, R&D | Sell | 8,942 | $203.20 | $1.82M | 12,882-41% |
| Dec 1, 2021 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 5,000 | $228.72 | $1.14M | 2,760-64% |
| Nov 30, 2021 | Glenn Gregory M | President, R&D | Sell | 2,083 | $218.07 | $454.2K | 5,959-26% |
| Nov 24, 2021 | Glenn Gregory M | President, R&D | Sell | 8,250 | $199.50 | $1.65M | 11,511-42% |
| Nov 17, 2021 | Glenn Gregory M | President, R&D | Sell | 9,433 | $169.79 | $1.60M | 11,811-44% |
| Nov 12, 2021 | Glenn Gregory M | President, R&D | Sell | 8,250 | $167.53 | $1.38M | 11,911-41% |
| Nov 5, 2021 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 5,000 | $200.00 | $1.00M | 2,760-64% |
| Nov 4, 2021 | Glenn Gregory M | President, R&D | Sell | 8,250 | $183.82 | $1.52M | 11,711-41% |
| Nov 3, 2021 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 5,000 | $163.08 | $815.4K | 7,360-40% |
| Nov 2, 2021 | Glenn Gregory M | President, R&D | Sell | 680 | $148.34 | $100.9K | 4,702 |
| Oct 28, 2021 | Glenn Gregory M | President, R&D | Sell | 10,334 | $132.73 | $1.37M | 12,895-44% |
| Oct 21, 2021 | Glenn Gregory M | President, R&D | Sell | 8,250 | $165.14 | $1.36M | 10,720-43% |
| Oct 19, 2021 | Glenn Gregory M | President, R&D | Sell | 1,183 | $170.00 | $201.1K | 4,061 |
| Oct 14, 2021 | Glenn Gregory M | President, R&D | Sell | 8,250 | $163.18 | $1.35M | 11,311-42% |
| Oct 7, 2021 | Glenn Gregory M | President, R&D | Sell | 8,250 | $174.41 | $1.44M | 10,840-43% |
| Oct 5, 2021 | Erck Stanley C | President and CEO | Sell | 91,829 | $175.59 | $16.12M | 72,176-56% |
| Oct 5, 2021 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 5,000 | $174.89 | $874.5K | 7,360-40% |
| Oct 1, 2021 | Glenn Gregory M | President, R&D | Sell | 693 | $207.25 | $143.6K | 4,703 |
| Sep 29, 2021 | Glenn Gregory M | President, R&D | Sell | 2,083 | $234.43 | $488.3K | 6,087-25% |
| Sep 29, 2021 | Trizzino John | EVP, CCO and CBO | Sell | 15,002 | $222.27 | $3.33M | 9,733-61% |
| Sep 24, 2021 | MOTT DAVID M | Director | Sell | 24,961 | $252.90 | $6.31M | 59,233-30% |
| Sep 22, 2021 | Trizzino John | EVP, CCO and CBO | Sell | 15,000 | $227.47 | $3.41M | 7,556-67% |
| Sep 17, 2021 | Glenn Gregory M | President, R&D | Sell | 1,183 | $229.34 | $271.3K | 5,182 |
| Sep 17, 2021 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 5,000 | $229.44 | $1.15M | 5,606-47% |
| Sep 15, 2021 | Trizzino John | EVP, CCO and CBO | Sell | 14,998 | $235.95 | $3.54M | 7,788-66% |
| Sep 3, 2021 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 5,000 | $247.97 | $1.24M | 5,606-47% |
Showing 1–50 of 73
1 / 2
NVAX Insider Buying Activity
The following table shows recent insider purchases of Novavax, Inc. (NVAX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 14, 2023 | Glenn Gregory M | President, R&D | Buy | 6,000 | $7.17 | $43.0K | 14,473+71% |
NVAX Insider Selling Activity
The following table shows recent insider sales of Novavax, Inc. (NVAX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 23, 2026 | Jacobs John C | President and CEO | Sell | 39,132 | $9.17 | $358.8K | 0 |
| Dec 11, 2025 | Casey Mark J | EVP, Chief Legal Officer | Sell | 12,713 | $6.69 | $85.0K | 0 |
| Nov 11, 2025 | Draghia-Akli Ruxandra | Section 16 | Sell | 6,048 | $7.40 | $44.8K | 0 |
| Mar 7, 2025 | Kelly James Patrick | EVP, CFO and Treasurer | Sell | 5,904 | $8.34 | $49.2K | 0 |
| Mar 7, 2025 | Trizzino John | President and COO | Sell | 13,954 | $8.34 | $116.4K | 0 |
| Mar 1, 2025 | Casey Mark J | EVP, Chief Legal Officer | Sell | 1,214 | $8.33 | $10.1K | 0 |
| Mar 1, 2025 | Jacobs John C | President and CEO | Sell | 38,451 | $8.33 | $320.3K | 0 |
| Mar 1, 2025 | Kelly James Patrick | EVP, CFO and Treasurer | Sell | 28,337 | $8.33 | $236.0K | 0 |
| Mar 1, 2025 | O'Hara Elaine | EVP, Chief Strategy Officer | Sell | 16,344 | $8.33 | $136.1K | 0 |
| Mar 1, 2025 | Trizzino John | President and COO | Sell | 23,185 | $8.33 | $193.1K | 0 |
| Jan 2, 2025 | King Rachel K. | Sell | 4,150 | $9.02 | $37.4K | 14,770 | |
| Jan 2, 2025 | YOUNG JAMES F | Sell | 10,000 | $8.22 | $82.2K | 57,160 | |
| Jun 25, 2024 | YOUNG JAMES F | Sell | 7,500 | $14.09 | $105.7K | 61,760 | |
| Jun 21, 2024 | YOUNG JAMES F | Sell | 7,500 | $13.72 | $102.9K | 70,367 | |
| Jun 20, 2024 | Dubovsky Filip | President, R&D | Sell | 13,904 | $14.47 | $201.2K | 68,017 |
| May 15, 2024 | Dubovsky Filip | President, R&D | Sell | 47,312 | $13.90 | $657.6K | 38,953-55% |
| Apr 4, 2022 | YOUNG JAMES F | Director | Sell | 12,500 | $73.58 | $919.8K | 66,145 |
| Jan 5, 2022 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 5,000 | $140.91 | $704.5K | 8,445-37% |
| Jan 4, 2022 | YOUNG JAMES F | Director | Sell | 3,750 | $144.16 | $540.6K | 75,090 |
| Dec 22, 2021 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 5,000 | $230.00 | $1.15M | 3,845-57% |
| Dec 16, 2021 | Glenn Gregory M | President, R&D | Sell | 1,686 | $174.13 | $293.6K | 7,232 |
| Dec 9, 2021 | Glenn Gregory M | President, R&D | Sell | 8,250 | $170.14 | $1.40M | 12,111-41% |
| Dec 3, 2021 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 5,000 | $196.19 | $980.9K | 7,069-41% |
| Dec 2, 2021 | Glenn Gregory M | President, R&D | Sell | 8,942 | $203.20 | $1.82M | 12,882-41% |
| Dec 1, 2021 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 5,000 | $228.72 | $1.14M | 2,760-64% |
| Nov 30, 2021 | Glenn Gregory M | President, R&D | Sell | 2,083 | $218.07 | $454.2K | 5,959-26% |
| Nov 24, 2021 | Glenn Gregory M | President, R&D | Sell | 8,250 | $199.50 | $1.65M | 11,511-42% |
| Nov 17, 2021 | Glenn Gregory M | President, R&D | Sell | 9,433 | $169.79 | $1.60M | 11,811-44% |
| Nov 12, 2021 | Glenn Gregory M | President, R&D | Sell | 8,250 | $167.53 | $1.38M | 11,911-41% |
| Nov 5, 2021 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 5,000 | $200.00 | $1.00M | 2,760-64% |
| Nov 4, 2021 | Glenn Gregory M | President, R&D | Sell | 8,250 | $183.82 | $1.52M | 11,711-41% |
| Nov 3, 2021 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 5,000 | $163.08 | $815.4K | 7,360-40% |
| Nov 2, 2021 | Glenn Gregory M | President, R&D | Sell | 680 | $148.34 | $100.9K | 4,702 |
| Oct 28, 2021 | Glenn Gregory M | President, R&D | Sell | 10,334 | $132.73 | $1.37M | 12,895-44% |
| Oct 21, 2021 | Glenn Gregory M | President, R&D | Sell | 8,250 | $165.14 | $1.36M | 10,720-43% |
| Oct 19, 2021 | Glenn Gregory M | President, R&D | Sell | 1,183 | $170.00 | $201.1K | 4,061 |
| Oct 14, 2021 | Glenn Gregory M | President, R&D | Sell | 8,250 | $163.18 | $1.35M | 11,311-42% |
| Oct 7, 2021 | Glenn Gregory M | President, R&D | Sell | 8,250 | $174.41 | $1.44M | 10,840-43% |
| Oct 5, 2021 | Erck Stanley C | President and CEO | Sell | 91,829 | $175.59 | $16.12M | 72,176-56% |
| Oct 5, 2021 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 5,000 | $174.89 | $874.5K | 7,360-40% |
| Oct 1, 2021 | Glenn Gregory M | President, R&D | Sell | 693 | $207.25 | $143.6K | 4,703 |
| Sep 29, 2021 | Glenn Gregory M | President, R&D | Sell | 2,083 | $234.43 | $488.3K | 6,087-25% |
| Sep 29, 2021 | Trizzino John | EVP, CCO and CBO | Sell | 15,002 | $222.27 | $3.33M | 9,733-61% |
| Sep 24, 2021 | MOTT DAVID M | Director | Sell | 24,961 | $252.90 | $6.31M | 59,233-30% |
| Sep 22, 2021 | Trizzino John | EVP, CCO and CBO | Sell | 15,000 | $227.47 | $3.41M | 7,556-67% |
| Sep 17, 2021 | Glenn Gregory M | President, R&D | Sell | 1,183 | $229.34 | $271.3K | 5,182 |
| Sep 17, 2021 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 5,000 | $229.44 | $1.15M | 5,606-47% |
| Sep 15, 2021 | Trizzino John | EVP, CCO and CBO | Sell | 14,998 | $235.95 | $3.54M | 7,788-66% |
| Sep 3, 2021 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 5,000 | $247.97 | $1.24M | 5,606-47% |
NVAX Insiders
Similar Stocks to NVAX
VRTX
Vertex Pharmaceuticals Incorporated
$436.80-3.02%
$114.32B
REGN
Regeneron Pharmaceuticals, Inc.
$699.83-1.87%
$73.44B
ALNY
Alnylam Pharmaceuticals, Inc.
$289.07-1.46%
$39.18B
RVMD
Revolution Medicines, Inc.
$145.16-2.80%
$31.78B
INSM
Insmed Incorporated
$109.78-5.14%
$25.06B
UTHR
United Therapeutics Corporation
$568.58-1.47%
$24.13B
ROIV
Roivant Sciences Ltd.
$29.29-0.08%
$20.96B
MRNA
Moderna, Inc.
$49.04-2.34%
$19.46B